Utvidet genpanelanalyse av vev og liquid biopsi i pasientbehandling

Her presenteres tre pasienttilfeller hvor NGS-basert diagnostikk (utvidet genpanelanalyse, comprehensive genomic profiling, CGP) har blitt benyttet til å identifisere nye mutasjoner, støtte behandlingsvalg og identifisere pasienter som mulige kandidater for deltagelse i kliniske studier.

Referanser:

Dudnik E, et al. (2016) J Clin Neurosci 26:46–9, Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy

Peled, N., et al. (2012) J Thorac Oncol 7:e14-6, Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non–Small-Cell Lung Cancer

Peled, N., et al. (2013) J Thorac Oncol 8:e112-3, Effective Crizotinib Schedule for Brain Metastases in ALK Rearrangement Metastatic Non–Small-Cell Lung Cancer

Peled, N., et al. (2017) J Thorac Oncol 12:e81-4, Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR-Mutated Lung Cancer